Veru Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
VERU Nasdaq 2840 verupharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Veru Inc.

Veru to Present Two Abstracts at ObesityWeek 2025 - Oct 31st, 2025 6:30 am
Veru Announces Pricing of $25 Million Public Offering - Oct 30th, 2025 6:00 am
Veru Announces Proposed Public Offering - Oct 29th, 2025 2:01 pm
October 2025's Noteworthy Penny Stocks - Oct 8th, 2025 12:05 pm
Onconetix announces financing through private placement, debt settlement - Sep 27th, 2025 6:40 am
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. - Sep 26th, 2025 6:30 am
Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity - Sep 23rd, 2025 6:30 am
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm - Aug 15th, 2025 7:20 am
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - Aug 12th, 2025 4:30 am
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology - Aug 11th, 2025 2:01 pm
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study - Aug 11th, 2025 6:30 am
Veru Announces Reverse Stock Split - Aug 6th, 2025 6:30 am
Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th - Aug 5th, 2025 6:30 am
Veru to Participate in the 2025 BTIG Virtual Biotech Conference - Jul 22nd, 2025 6:30 am
Veru And Two Other Penny Stocks To Consider - Jun 26th, 2025 12:05 pm
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation - Jun 24th, 2025 6:30 am
One Veru Insider Raised Stake By 150% In Previous Year - Jun 22nd, 2025 6:28 am
Veru to Participate in the Virtual BTIG Obesity Health Forum - Jun 11th, 2025 6:30 am
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone - May 28th, 2025 4:30 am
Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ... - May 9th, 2025 1:08 am